-
A Cost per Responder Analysis of Lipid-Lowering Therapies in Patients With Established Atherosclerotic Cardiovascular Disease in Italy
Sep 9, 2025, 16:22 PM -
A Review of Cost Comparisons Submitted to NICE Since the Introduction of the Proportional Approach to Technology Appraisal
Sep 9, 2025, 16:22 PM -
Multistakeholder Engagement to Codevelop Specifications for Economic Models: The MASH Case Study
Sep 9, 2025, 16:22 PM -
Turning the Tables: AI Halves Table Extraction Time in HEOR Systematic Reviews
Sep 9, 2025, 16:22 PM -
Leveling the Field: How the MFN Could Transform Drug Pricing
Sep 9, 2025, 16:22 PM -
Global Pricing Meets Domestic Policy: Analyzing the Financial Impact of the Most-Favored Nation Approach on the United States Medicine Prices
Sep 9, 2025, 16:22 PM -
Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece
Sep 9, 2025, 16:22 PM -
Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era
Sep 9, 2025, 16:22 PM -
The Burden of Patients With Severe Asthma: A Comparison Between Patients Treated With and Eligible for Monoclonal Antibodies Through a Retrospective Observational Analysis of Italian Real-World Data
Sep 9, 2025, 16:22 PM -
Evidence Strategy Starts Early: Integrating HTA Needs Through PICO Simulation in Metastatic Castration-Resistant Prostate Cancer
Sep 9, 2025, 16:22 PM -
The Artificial Intelligence Era in Health Economic Modeling
Sep 9, 2025, 16:22 PM -
Systematic Literature Review (SLR) of Efficacy, Health-Related Quality of Life (HRQoL), and Safety of the First-Line (1L) Treatments of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Rozanolixizumab for the Treatment of Generalized Myasthenia Gravis (gMG) in Greece
Sep 9, 2025, 16:22 PM -
Navigating Reimbursement Challenges for Pharmacological Interventions in Celiac Disease: Lessons From Analogous Conditions
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review on Economic Evaluations and Cost-Effectiveness of Second-Line Treatment Options for Immune Thrombocytopenia
Sep 9, 2025, 16:22 PM -
Patient-Reported Outcomes Used for Regulatory Approval of Oncology Medicinal Products in the European Union Between 2021 and 2024: A Review Update
Sep 9, 2025, 16:22 PM -
Viable Rate of Return for Social Impact Bonds Supporting Research and Development of Gene Therapies for Rare Conditions
Sep 9, 2025, 16:22 PM -
Characterizing the Use of Janus Kinase Inhibitors (JAKi) in Five European Countries: A Drug Utilization Study
Sep 9, 2025, 16:22 PM -
Competing Beyond the First Mover: How Late to Market Analogues Navigate Pricing and Access in Major Global Markets
Sep 9, 2025, 16:22 PM -
The Association Between COVID-19 Vaccination and the Healthcare Resource Use Related to COVID-19 in Typical Rural Residents in Japan
Sep 9, 2025, 16:22 PM
